{"DataElement":{"publicId":"7675280","version":"1","preferredName":"Gastrointestinal Stromal Tumor Immunohistochemical Testing Performed Other Specify","preferredDefinition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases._A question asking if any immunohistochemical tests were performed during the study._Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"7671807v1.0:6832577v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7671807","version":"1","preferredName":"Gastrointestinal Stromal Tumor Immunohistochemical Testing Performed","preferredDefinition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases._A question asking if any immunohistochemical tests were performed during the study.","longName":"2875746v1.0:7643962v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"2875746","version":"1","preferredName":"Gastrointestinal Stromal Tumor","preferredDefinition":"GIST. A type of tumor that usually begins in cells in the wall of the gastrointestinal tract.  It can be benign or malignant.","longName":"C3868","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastrointestinal Stromal Tumor","conceptCode":"C3868","definition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69CC3F8C-54D3-DD89-E040-BB89AD4301CB","latestVersionIndicator":"Yes","beginDate":"2009-05-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-05-13","modifiedBy":"ONEDATA","dateModified":"2009-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7643962","version":"1","preferredName":"Was Immunohistochemical Testing Performed","preferredDefinition":"A question asking if any immunohistochemical tests were performed during the study.","longName":"C159638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Was Immunohistochemical Testing Performed","conceptCode":"C159638","definition":"A question asking if any immunohistochemical tests were performed during the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0F8673F-2CA3-55A2-E053-4EBD850A8CE8","latestVersionIndicator":"Yes","beginDate":"2021-04-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-04-27","modifiedBy":"ONEDATA","dateModified":"2021-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3CAF836-D441-09C1-E053-4EBD850A678A","latestVersionIndicator":"Yes","beginDate":"2021-06-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-02","modifiedBy":"COLBERTM","dateModified":"2022-06-07","changeDescription":null,"administrativeNotes":"6/7/22 mr Released per CPTAC/Nicolletteâ€™s XLS review as part of quarterly metrics review.","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6832577","version":"1","preferredName":"Other Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"OTH_SPEC","context":"OCCPR","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8E9A3B10-BC5A-67B5-E053-F662850A6556","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-26","modifiedBy":"KNABLEJ","dateModified":"2019-08-19","changeDescription":"8/19/19 jk released for reuse by Theradex.  7/26/19 jk created for use on multiple CPTAC CRF questions.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"7218984","version":"1","longName":"Soft Tissue","context":"OCCPR"},{"publicId":"7634335","version":"1","longName":"SAR Baseline","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Other, specify","type":"Preferred Question Text","description":"Other, specify","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3DD0ADC-04ED-695B-E053-4EBD850ACBA7","latestVersionIndicator":"Yes","beginDate":"2021-06-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-06-03","modifiedBy":"SOKKERL","dateModified":"2023-09-25","changeDescription":null,"administrativeNotes":"9/24/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"}}